The total return over the past 12 months is +19.00% vs. +16.94% for the S&P 500. So far it's up +5.78% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +19.00% | +53.88% | +16.41% | +7.89% | N/A | N/A |
| Total Return CAGR | +19.00% | +53.88% | +16.41% | +7.89% | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
DiaMedica Therapeutics Inc. (DMAC)
| Year | Start price | End price | DMAC Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.96 | $8.42 | +5.78% | +14.51% | (8.73%) |
| 2025 | $5.43 | $7.96 | +46.59% | +17.72% | +28.87% |
| 2024 | $2.84 | $5.43 | +91.20% | +24.89% | +66.31% |
| 2023 | $1.58 | $2.84 | +79.75% | +26.19% | +53.56% |
| 2022 | $3.73 | $1.58 | (57.64%) | (18.17%) | (39.47%) |
| 2021 | $10.14 | $3.73 | (63.21%) | +28.74% | (91.95%) |
| 2020 | $4.85 | $10.14 | +109.07% | +18.37% | +90.70% |
| 2019 | $2.91 | $4.85 | +66.67% | +31.22% | +35.45% |
| 2018 | $5.00 | $2.91 | (41.80%) | (4.56%) | (37.24%) |
| 2017 | $2.20 | $5.00 | +127.27% | +21.70% | +105.57% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
